GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Double Bond Pharmaceutical International AB (XSAT:DBP B) » Definitions » Enterprise Value

Double Bond Pharmaceutical International AB (XSAT:DBP B) Enterprise Value : kr8.67 Mil (As of Jun. 24, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Double Bond Pharmaceutical International AB Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Double Bond Pharmaceutical International AB's Enterprise Value is kr8.67 Mil. Double Bond Pharmaceutical International AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was kr-11.70 Mil. Therefore, Double Bond Pharmaceutical International AB's EV-to-EBIT ratio for today is -0.74.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Double Bond Pharmaceutical International AB's Enterprise Value is kr8.67 Mil. Double Bond Pharmaceutical International AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was kr-11.53 Mil. Therefore, Double Bond Pharmaceutical International AB's EV-to-EBITDA ratio for today is -0.75.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Double Bond Pharmaceutical International AB's Enterprise Value is kr8.67 Mil. Double Bond Pharmaceutical International AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was kr0.65 Mil. Therefore, Double Bond Pharmaceutical International AB's EV-to-Revenue ratio for today is 13.32.

EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Double Bond Pharmaceutical International AB's Enterprise Value is kr8.67 Mil. Double Bond Pharmaceutical International AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 was kr0.00 Mil. Therefore, Double Bond Pharmaceutical International AB's EV-to-FCF ratio for today is .


Double Bond Pharmaceutical International AB Enterprise Value Historical Data

The historical data trend for Double Bond Pharmaceutical International AB's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Double Bond Pharmaceutical International AB Enterprise Value Chart

Double Bond Pharmaceutical International AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 110.99 39.69 35.77 65.30 36.40

Double Bond Pharmaceutical International AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 71.57 44.19 48.66 36.40 28.54

Competitive Comparison of Double Bond Pharmaceutical International AB's Enterprise Value

For the Biotechnology subindustry, Double Bond Pharmaceutical International AB's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Double Bond Pharmaceutical International AB's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Double Bond Pharmaceutical International AB's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Double Bond Pharmaceutical International AB's Enterprise Value falls into.


;
;

Double Bond Pharmaceutical International AB Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Double Bond Pharmaceutical International AB's Enterprise Value for the fiscal year that ended in Dec. 2024 is calculated as

Double Bond Pharmaceutical International AB's Enterprise Value for the quarter that ended in Mar. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Double Bond Pharmaceutical International AB  (XSAT:DBP B) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Double Bond Pharmaceutical International AB's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=8.670/-11.702
=-0.74

Double Bond Pharmaceutical International AB's current Enterprise Value is kr8.67 Mil.
Double Bond Pharmaceutical International AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-11.70 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Double Bond Pharmaceutical International AB's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=8.670/-11.527
=-0.75

Double Bond Pharmaceutical International AB's current Enterprise Value is kr8.67 Mil.
Double Bond Pharmaceutical International AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-11.53 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Double Bond Pharmaceutical International AB's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=8.670/0.651
=13.32

Double Bond Pharmaceutical International AB's current Enterprise Value is kr8.67 Mil.
Double Bond Pharmaceutical International AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.65 Mil.

4. EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow.

Double Bond Pharmaceutical International AB's EV-to-FCF for today is:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=8.670/0
=

Double Bond Pharmaceutical International AB's current Enterprise Value is kr8.67 Mil.
Double Bond Pharmaceutical International AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Double Bond Pharmaceutical International AB Enterprise Value Related Terms

Thank you for viewing the detailed overview of Double Bond Pharmaceutical International AB's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Double Bond Pharmaceutical International AB Business Description

Traded in Other Exchanges
N/A
Address
Virdings Alle 32B, Uppsala, SWE, 75450
Double Bond Pharmaceutical International AB is a pharmaceutical company. The company develops and commercializes approaches for the treatment of cancers, infections, autoimmune diseases, and other life-threatening disorders.

Double Bond Pharmaceutical International AB Headlines

No Headlines